Tazemetostat

What is Tazemetostat?

• Tazemetostat (Tazverik) is a methyltransferase inhibitor with potential antineoplastic activity.

What are the uses of this medicine?

This medicine is used to treat:

• adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.
• adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure Tazverik is right for you.
• adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options.

How does this medicine work?

• Upon oral administration, E7438 selectively inhibits the activity of both wild-type and mutated forms of EZH2.
• Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
• This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells.
• EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.

Who Should Not Use this medicine ?

• This medicine have no usage limitations.

What drug interactions can this medicine cause?

• Avoid coadministration of strong or moderate CYP3A inhibitors with Tazverik. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce Tazverik dose.
• Avoid coadministration of moderate and strong CYP3A inducers with Tazverik.
• Coadministration of Tazverik with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• Select patients with R/R FL for treatment with Tazverik based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens.

Recommended Dosage

• Recommended dosage is 800 mg taken orally twice daily with or without food.

Administration

• Take Tazverik exactly as your healthcare provider tells you.
• Take Tazverik 2 times each day.
• Take Tazverik with or without food.
• Swallow Tazverik tablets whole. Do not cut, crush, or chew tablets.
• If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.
• Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with Tazverik if you get certain side effects.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form: As Tablets: 200 mg

This medicine is available in fallowing brand namesː

• Tazverik

What side effects can this medication cause?

The most common side effects of this medicine include:

• tiredness
• bone and muscle pain
• cold-like symptoms (upper respiratory infection)
• nausea
• stomach (abdominal) pain

What special precautions should I follow?

• Tazverik increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, and acute myeloid leukemia. Monitor patients long-term for the development of secondary malignancies.
• This medicine may cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• Tazverik can cause fetal harm when administered to pregnant women.
• There are no available data on Tazverik use in pregnant women to inform the drug-associated risk.

Can this medicine be used in children?

• The safety and effectiveness of Tazverik have been established in pediatric patients aged 16 years and older (adolescents) with metastatic or locally advanced epithelioid sarcoma.
• The safety and effectiveness of Tazverik in pediatric patients aged less than 16 years have not been established.

What should I know about storage and disposal of this medication?

• Do not store Tazverik tablets above 86°F (30°C).
• Keep Tazverik and all medicines out of the reach of children.

Clinical Trials Using Tazemetostat

Check for ACTIVE CLINICAL TRIALS

• Dailymed label info on Tazemetostat
• FDA Tazemetostat